0001446847 false IRONWOOD PHARMACEUTICALS INC 0001446847 2021-06-02 2021-06-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report Pursuant to 

Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):

June 2, 2021

 

IRONWOOD PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-34620   04-3404176
(State or other jurisdiction     (I.R.S. Employer
of incorporation)   (Commission File Number)   Identification Number)

 

100 Summer Street, Suite 2300        
Boston, Massachusetts       02110
(Address of principal        
executive offices)       (Zip code)

 

(617) 621-7722

(Registrant’s telephone number,

including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A common stock, $0.001 par value IRWD Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

  

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 2, 2021, at the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Ironwood Pharmaceuticals, Inc. (the “Company”), the stockholders of the Company voted on the following proposals:

 

·Election of three Class I directors and four Class II directors of the Company, each to serve a one-year term;

 

·Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting; and

 

·Ratification of the audit committee’s selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2021.

 

The final voting results for the Annual Meeting are as follows:

 

1.The stockholders elected Mark G. Currie, Ph.D., Alexander J. Denner, Ph.D. and Jon R. Duane as Class I directors and Marla L. Kessler, Catherine Moukheibir, Lawrence S. Olanoff, M.D., Ph.D. and Jay P. Shepard as Class II directors, each to serve on the board of directors of the Company for a one-year term until the annual meeting of stockholders to be held in 2022 or until his or her successor is duly elected and qualified or until his or her death, resignation or removal, based on the following votes:

 

Director Nominee  For   Withheld   Broker Non-Votes 
Class I Directors               
                
Mark G. Currie, Ph.D.   132,969,794    765,518    10,123,904 
                
Alexander J. Denner, Ph.D.   123,548,263    10,187,049    10,123,904 
                
Jon R. Duane   132,705,250    1,030,062    10,123,904 
                
Class II Directors               
                
Marla L. Kessler   132,987,091    748,221    10,123,904 
                
Catherine Moukheibir   132,993,027    742,285    10,123,904 
                
Lawrence S. Olanoff, M.D., Ph.D.   132,666,084    1,069,228    10,123,904 
                
Jay P. Shepard   133,077,585    657,727    10,123,904 

 

2.The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting, based on the following votes:

 

For   Against   Abstain   Broker Non-Votes 
 131,908,441    780,963    1,045,908    10,123,904 

 

3.The stockholders ratified the audit committee’s selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2021, based on the following votes:

 

For   Against   Abstain   Broker Non-Votes 
 142,743,134    1,093,669    22,413    0 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Ironwood Pharmaceuticals, Inc.
   
     
   Dated: June 3, 2021 By: /s/ Gina Consylman
    Name: Gina Consylman
    Title: Senior Vice President, Chief Financial Officer